enzyme inhibitor therapy
Sponsors
Jonsson Comprehensive Cancer Center, SWOG Cancer Research Network, Ohio State University Comprehensive Cancer Center, Eastern Cooperative Oncology Group, University of Rochester
Conditions
Esophageal CancerGastrointestinal Carcinoid TumorHigh-grade Squamous Intraepithelial LesionIslet Cell CarcinomaKidney CancerLeukemiaLymphomaMetastatic Malignant Solid Neoplasm
Phase 1
Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
TerminatedNCT00124644
Start: 2006-03-31End: 2008-01-31Target: 30Updated: 2013-05-03
Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer
WithdrawnNCT00268255
Updated: 2013-04-16
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
CompletedNCT03229278
Start: 2017-10-03End: 2022-10-30Updated: 2023-12-06
Phase 2
BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer
WithdrawnNCT00040989
Updated: 2013-07-10
S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix
WithdrawnNCT00072540
Updated: 2013-11-08
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
WithdrawnNCT00227773
Updated: 2015-10-08
Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery
TerminatedNCT00258297
Start: 2004-04-30End: 2006-11-30Target: 30Updated: 2013-10-16
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
TerminatedNCT00265928
Target: 46Updated: 2008-01-28
Talabostat in Treating Patients With Metastatic Kidney Cancer
WithdrawnNCT00489710
Start: 2006-12-31End: 2007-05-30Updated: 2023-08-22